Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: satiety and postprandial hormone signaling
Also known as: IAPP, Islet amyloid polypeptide
Amylin (islet amyloid polypeptide, IAPP) is a hormone co-secreted with insulin by pancreatic beta cells, slowing gastric emptying, suppressing glucagon secretion, and promoting satiety. Its FDA-approved synthetic analog pramlintide (Symlin, approved 2005) is used as an adjunct to mealtime insulin. The same amylin-receptor mechanism underlies the newer generation of long-acting amylin agonists in active development, including cagrilintide, the cagrilintide+semaglutide combination CagriSema, and the newly emerging eloralintide (see those records) - making amylin biology directly relevant to several of the newest, most newsworthy compounds in this catalog.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: FDA approval history (pramlintide, 2005); amylin-receptor mechanism literature shared with cagrilintide/CagriSema/eloralintide
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
Native amylin is used as a mechanistic laboratory peptide; no standardized human administration protocol is established because of aggregation and short stability
Context: amylin receptor pharmacology review
Route safety: Non-human or laboratory exposure. It cannot be converted into a human dose.
No route-specific amount established in the reviewed record.
Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
The interaction entry is a safety flag derived from pramlintide labeling; native amylin itself has no standardized human-use protocol.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention Amylin or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.